

Tool 3: Antiviral Prophylaxis and Treatment for Residents

The client’s most responsible provider (MRP) should ensure all appropriate blood work is completed. They should consult with their pharmacist to discuss the recommended antiviral prophylaxis and treatment dosage for influenza based on client's medical history (e.g., renal dialysis, allergies).

Sites should work with their pharmacist so the Care Community will be ready to give anti-Influenza medication on a few hours’ notice to all residents that are eligible for treatment or prophylaxis.

- Oseltamivir treatment as soon as possible, preferably within 4 to 6 hours of recommendation;
- Oseltamivir prophylaxis as soon as possible, ideally within 24 hours of recommendation

A RION is not required for pharmacy to dispense antivirals. A letter is available (Tool 5) in this package outlining that pharmacies should not require a RION to dispense antivirals in the event of an outbreak

- This pre-printed order (PPO) for COVID-19 will be only valid for 14 days OR when an outbreak has been declared over, whichever is soon
 - After 14 days contact physician for assessment and a newly signed COVID PPO will be required
- Refer to Paxlovid DST for COVID-19 treatment. Please note there is no prophylaxis anti-viral for COVID-19 infections

Refer to following resources and Fraser Health Decision Supporting Tools (DST) for anti-viral prophylaxis and treatment recommendations:

Fraser Health Owned and Operated Sites	
Influenza	INFLUENZA DST
COVID-19	COVID-19 PPO PAXLOVID DST BCCDC: Treatments (bccdc.ca)
Affiliated and Non-Affiliated Sites	
Influenza	Care homes that do have access to Fraser Health’s internal website can access pre-printed orders and DSTs here: Long-Term Care Contracts and Services - Clinical Resources (fraserhealth.ca) <ul style="list-style-type: none"> • To gain access or questions contact the Regional Clinical Nurse Educator (CNE) for LTC (FHAResidentialClinicalNurseEducators@fraserhealth.ca)
COVID-19	
Drug monographs and other resources	
Relenza (2018) Tamiflu Product Monograph (2022) Influenza Antiviral Medications – CDC Canadian Pandemic Influenza Plan for Health Sector	